MeiraGTx adds Alan M. Sebulsky, former Adage Capital manager, to board
The genetic medicines company named Sebulsky a Class I director effective September 23, 2026, with a term running until the 2028 annual meeting.
SEC filing
Latest
4 stories
Wednesday, September 23
Wednesday, September 2
Parabilis Medicines' chief medical officer to depart in September
Fawzi Benzaghou, M.D., will leave the company on September 30, 2026, under a mutual agreement disclosed in an 8-K filing.
SEC filing
Tuesday, August 25
Parabilis Medicines adds oncology veteran Craig Tendler to board
The clinical-stage biopharma named Craig L. Tendler, M.D., a former Johnson & Johnson oncology leader, as a new Class II director on August 22, 2026.
SEC filing
Thursday, August 13
Parabilis reports Q2 2026 results, $1.1B cash, Regeneron pact
The company posted a $52.5 million quarterly net loss while advancing zolucatetide toward a planned Phase 3 desmoid tumor trial and detailing a new Regeneron collaboration.
SEC filing